Initial Experience With the Trevo NXT Stent Retriever by Etter, Manina M. et al.
ORIGINAL RESEARCH
published: 16 July 2021
doi: 10.3389/fneur.2021.704329















This article was submitted to
Stroke,
a section of the journal
Frontiers in Neurology
Received: 02 May 2021
Accepted: 11 June 2021
Published: 16 July 2021
Citation:
Etter MM, Möhlenbruch M,
Weyland CS, Pérez-García C,
Moreu M, Capasso F, Limbucci N,
Nikoubashman O, Wiesmann M,
Blackham K, Tsogkas I, Sporns P,
Ospel JM, Brehm A and
Psychogios M-N (2021) Initial
Experience With the Trevo NXT Stent
Retriever. Front. Neurol. 12:704329.
doi: 10.3389/fneur.2021.704329
Initial Experience With the Trevo NXT
Stent Retriever
Manina M. Etter 1, Markus Möhlenbruch 2, Charlotte S. Weyland 2, Carlos Pérez-García 3,
Manuel Moreu 3, Francesco Capasso 4, Nicola Limbucci 4, Omid Nikoubashman 5,
Martin Wiesmann 5, Kristine Blackham 1, Ioannis Tsogkas 1, Peter Sporns 1,
Johanna Maria Ospel 1, Alex Brehm 1 and Marios-Nikos Psychogios 1*
1Department of Neuroradiology, Clinic for Radiology and Nuclear Medicine, University Hospital Basel, Basel, Switzerland,
2Department of Neuroradiology, University Hospital Heidelberg, Heidelberg, Germany, 3Department of Neuroradiology,
Hospital Clínico San Carlos, Madrid, Spain, 4Neurovascular Interventional Unit, Careggi University Hospital, Florence, Italy,
5Department of Neuroradiology, University Hospital RWTH Aachen, Aachen, Germany
Background: The application of a new coating to the delivery wire of the Trevo retriever
has the potential to improve its handling. We therefore report our initial experience
with this new stent retriever for mechanical thrombectomy of large and medium
vessel occlusions.
Methods: We pooled data of four high-volume European stroke centers over the
time period from October 2020 to February 2021. Patients were included in our study
if the Trevo NXT stent retriever was used as a first-line device. Primary endpoints
were first-pass near-complete or complete reperfusion, defined as mTICI score of ≥2c.
Secondary endpoints were final reperfusion, National Institutes of Health Stroke Scale
(NIHSS) at 24 h and discharge, device malfunctions, complications during the procedure,
and subjective ratings of the interventionalists regarding device functionality.
Results: Eighty patients (39 women, mean age 74± 14 years) were eligible for our study.
Median NIHSS at admission was 15 (IQR, 8–19), and median Alberta Stroke Program
Early CT Score at baseline was 9 (IQR, 8–10). In 74 (93%) patients a primary combined
approach was used as first-line technique. First-pass near-complete reperfusion was
achieved in 43 (54%) and first-pass complete reperfusion in 34 (43%) patients. Final
near-complete reperfusion was achieved in 66 (83%) patients after a median of 1.5 (1–
3) passes, while final successful reperfusion was observed in 96% of our cases. We
observed no device malfunctions. Median NIHSS at discharge was 2 (IQR, 0–5), and 3
patients (4%) suffered a symptomatic intracranial hemorrhage.
Conclusions: Based on our initial data, we conclude that the Trevo NXT is
an effective and safe tool for mechanical thrombectomy especially when used for
combined approaches.
Keywords: ischemic stroke, mechanical thrombectomy, stent retriever, primary combined approaches, medium
vessel occlusion, large vessel occlusion
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INTRODUCTION
Mechanical thrombectomy is considered the standard of care
for ischemic strokes caused by large vessel occlusions (LVO)
(1). The main techniques can be generally divided into three
major categories: (I) use of a stent retriever (SR) and subsequent
withdrawal of the device with or without flow arrest by a
balloon-guide catheter (BGC); (II) direct aspiration technique
using a large-bore aspiration-catheter (ADAPT), placed at
the face of the clot; and (III) primary combined approaches
(PCA), where both an SR and an aspiration-catheter are used
intracranially with additional extracranial aspiration through the
guide catheter (2–4).
Among the different techniques for mechanical
thrombectomy, various SRs are used in combined approaches.
The Trevo ProVue SR is a well-established mechanical
thrombectomy device as several studies have confirmed its
efficacy in endovascular stroke therapy. In the Multicenter
Randomized CLinical trial of Endovascular treatment for Acute
ischemic stroke in the Netherlands (MR CLEAN), Trevo was
the most frequently used SR (5). In the Clinical Mismatch in
the Triage of Wake Up and Late Presenting Strokes Undergoing
Neurointervention With Trevo (DAWN) randomized trial,
which showed thrombectomy to be superior compared to
medical management alone, Trevo was the only SR used in
the interventional arm (6). The device was also assessed in the
Trevo retriever Registry, a prospective post-market study which
documented reperfusion success after mechanical thrombectomy
and functional outcomes at 90 days. Reperfusion success was
defined by a modified thrombolysis in cerebral infarction
(mTICI) score ≥2b, which was reached in 93% of the study
population. Furthermore, functional independence at 90 days
(defined as a modified Rankin Scale≤2) was documented in 55%
of patients (7).
In this retrospective study, we assessed the new-generation
Trevo SR (Trevo NXT) for endovascular therapy of ischemic
stroke due to large or medium vessel occlusions. We focused on
its efficacy and peri-interventional safety.
MATERIALS AND METHODS
Study Design and Patient Population
We pooled data of four high-volume European stroke centers
over the time period from October 2020 to February 2021.
Patients were included in our study if the Trevo NXT ProVue
SR (Stryker Neurovascular, Kalamazoo, MI, USA) was used as
the first-line device. No other inclusion or exclusion criteria
were applied.
The National Institutes of Health Stroke Scale (NIHSS) was
obtained at baseline, 24 h post procedure and at discharge by a
certified stroke neurologist. All angiographies were rated by the
treating interventionalist using themTICI (8) scale. Non-contrast
computed tomography (CT) or magnetic resonance imaging
(MRI) was regularly performed within 24 h after treatment or
immediately in symptomatic patients. Symptomatic intracranial
hemorrhage (sICH) was defined as an intracranial hemorrhage
that was associated with clinical deterioration, as documented by
an increase of ≥4 points on the NIHSS. In intubated patients,
sICH was defined by the European Cooperative Acute Stroke
Study-2 (ECASS-2) criteria as any parenchymal hematoma grade
I or larger (9).
As the company claims that the new Trevo NXT can
be delivered and retracted through the microcatheter or the
aspiration-catheter more easily compared to earlier Trevo
generations, we surveyed the involved interventionalists on
their subjective experience with the new device. The following
questions were used: (a) How easy was advancing the SR through
the microcatheter? (b) Could target placement of the SR be
achieved? (c) How easy was retrieving the SR into the aspiration-
catheter/BGC? and (d) In PCA, could a stable wedge position
be achieved, or was the SR accidentally withdrawn into the
aspiration-catheter? For questions (a) and (c) we used an evenly
distributed ordinal five-point scale (ranging from 1 = very easy,
2= easy, over 3= neutral, to 4= hard, and 5= very hard), while
(b) and (d) were yes/no questions. For this analysis, only cases in
which a PCA was used as the first-line approach were included.
The primary endpoint was first-pass complete or near-
complete reperfusion, defined as an mTICI ≥2c. Secondary
endpoints were final reperfusion, NIHSS at 24 h and discharge,
occurrence of sICH, device malfunctions, complications during
the procedure, and the subjective ratings of the interventionalists.
Endovascular Procedure
Procedures were performed under conscious sedation, local
anesthesia, or general anesthesia. Vital findings were monitored
by anesthesiologists or stroke neurologists in all patients during
the procedures. All procedures were done using a femoral artery
access. The treating physician was free to choose the first-line
technique, but in most cases the Stent retriever Assisted Vacuum
Extraction (SAVE) technique was used as described elsewhere (4).
Device Characteristics
The Trevo NXT ProVue retriever is a further development of
its predecessor, the Trevo XP ProVue retriever. While the stent
itself was not changed and still offers full radiopaque visibility, the
delivery wire received a new hydrophilic coated polymer jacket
which enables a smoother and easier delivery and improved
retraction into the aspiration-catheter. It is delivered through
a 0.021-inch microcatheter (the 3 × 25 mm retriever can also
be delivered through a 0.017-inch microcatheter). The device is
available in working lengths from 25 to 35 mm and diameters
from 3 to 6 mm. The wire length was increased to 200 cm, which
improves its compatibility with tri-axial setups.
Statistical Methods
Statistical analysis was performed using GraphPad Prism
9 (GraphPad Software, San Diego, CA, USA, https://www.
graphpad.com/, 2021). Parametric variables are stated as
mean ± standard deviation (SD). Non-parametric or ordinary
variables are presented as median and interquartile range (IQR).
No interference statistics were performed.
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TABLE 1 | Baseline characteristics of the patients.
Characteristics Values
No. of patients 80
Women, n (%) 39 (49%)
Age, mean ± SD 74 ± 14
NIHSS at admission, median (IQR) 15 (8–19)
Pre-stroke mRS, median (IQR) 0 (0–1)
ASPECTS at baseline, median (IQR) 9 (8–10)
Primary approach
Stent retriever + BGC, n (%) 5 (6%)
PCA, n (%) 47 (59%)
PCA + BGC, n (%) 27 (34%)
Stent retriever only, n (%) 1 (1%)
Occlusion location
ICA-T, n (%) 14 (18%)
M1, n (%) 38 (48%)
M2, n (%) 22 (28%)
BA, n (%) 4 (5%)
P2, n (%) 1 (1%)
VA, n (%) 1 (1%)
Tandem occlusion, n (%) 12 (15%)
Outcomes
NIHSS at 24 h, median (IQR) 4.5 (1.5–11)
NIHSS at discharge, median (IQR) 2 (0–5)
sICH, n (%) 3 (4%)
Secondary distal emboli, n (%) 4 (5%)
Emboli to new territory, n (%) 1 (1%)
ASPECTS, Alberta Stroke Program Early CT Score; BA, basilar artery; BGC, balloon-
guide catheter; ICA-T, internal carotid artery terminus; IQR, interquartile range; NIHSS,
National Institute of Health Stroke Scale; mRS, modified Rankin scale; PCA, primary
combined approach; SD, standard deviation; sICH, symptomatic intracranial hemorrhage;
VA, vertebral artery.
RESULTS
Out of 97 received data sheets, 80 patients were enrolled into
this study. Ten of the 97 patients were excluded due to ADAPT
being the first-line therapy, while in seven patients an SR other
than the Trevo NXT ProVue was used for the first maneuver.
All baseline characteristics are depicted in Table 1. Mean age was
74 ± 14 years, and 39 patients (49%) were female. The median
NIHSS at admission was 15 (IQR, 8–19). Occlusion sites were
internal carotid artery terminus (“ICA-T”) in 14 (18%), M1-
segment in 38 (47%), M2-segment in 22 (28%), basilar artery
in 4 (5%), P2-segment in 1 (1%), and vertebral artery in 1
(1%) patient. Median Alberta Stroke Program Early CT score
(ASPECTS) on initial imaging was 9 (IQR 8–10). The majority
of patients was treated either with a PCA (47/80) or PCA with
balloon-guide (27/80), while the rest was treated with SR only
(1/80) or with SR plus BGC (5/80). Most of the procedures
were performed under conscious sedation or local anesthesia
(67 patients). General anesthesia was used in the remaining 13
patients (16%).
First-pass complete or near-complete reperfusion (mTICI
≥2c) was achieved in 43 (54%)with complete reperfusion (mTICI
TABLE 2 | Angiographic results stratified by occluded vessel and overall vessels.
ICA-T M1 M2 Overall
No. of patients 14 38 22 80
First-pass reperfusion
mTICI ≥2b, n (%) 5 (36%) 25 (66%) 11 (50%) 51 (64%)
mTICI ≥2c, n (%) 4 (29%) 20 (53%) 10 (46%) 43 (54%)
mTICI 3, n (%) 2 (14%) 15 (40%) 8 (36%) 34 (43%)
Final reperfusion
mTICI ≥2b, n (%) 13 (93%) 36 (95%) 22 (100%) 77 (96%)
mTICI ≥2c, n (%) 12 (86%) 30 (79%) 19 (86%) 66 (83%)
mTICI 3, n (%) 7 (50%) 22 (58%) 13 (59%) 45 (56%)
No of passes, median
(IQR)
3 (1–4) 1 (1–2) 1 (1–2) 1.5 (1–3)
Groin
puncture–reperfusion
time (min), median, IQR
51 (33.8–82.5) 34 (22.3–52.8) 35 (22–57) 39 (23–58.5)
ICA-T, internal carotid artery terminus; IQR, interquartile range; mTICI, modified
thrombolysis in cerebral infarction.
TABLE 3 | Per pass reperfusion results.
Pass # 1 2 3 4 5 6
Number of patients 80 34 20 14 8 5
mTICI <2b, n (%) 29 (36%) 18 (53%) 12 (60%) 8 (54%) 5 (63%) 3 (60%)
mTICI ≥2b, n (%) 51 (64%) 16 (47%) 8 (40%) 6 (46%) 3 (37%) 2 (40%)
mTICI ≥2c, n (%) 43 (54%) 12 (35%) 5 (25%) 3 (23%) 1 (12%) 1 (20%)
mTICI 3, n (%) 34 (43%) 7 (21%) 2 (10%) 2 (15%) 0 (0%) 0 (0%)
mTICI, modified thrombolysis in cerebral infarction.
3) in 34 (43%) patients. The final complete or near-complete
reperfusion (mTICI≥2c) was observed in 66 (83%) and complete
reperfusion (mTICI 3) in 45 (56%) patients after a median of 1.5
passes (IQR, 1–3). The rate of successful reperfusion (mTICI ≥
2b) was 64% after one pass and 96% at the end of the procedure
(Table 2). The overall median time from groin puncture to
reperfusion was 39min (IQR, 23–58.5). We documented 1 (1%)
embolus in new territory (initial M1 to A1), and in 4 cases
(5%) distal emboli were observed. In 3 patients (4%) an sICH
was observed. In 2 cases the intracranial hemorrhage (ICH) was
observed immediately on the post-mechanical thrombectomy
scan in the angio-suite, while in the third case no immediate scan
after MT was performed. It was observed on the first follow-
up CT 4.5 h after the intervention. One ICH was mainly an
extensive subarachnoid hemorrhage (SAH) in the basal cisterns
and hemispheric sulci with small parenchymal hematoma in the
left basal ganglia (affecting putamen) and insula; the other 2
ICHs were mainly parenchymal hematomas within the infarct
area (both media territory left). In the case with the SAH no
intravenous lysis was given, while in the other 2 cases it was given
prior to the intervention. None of the sICHs were rated to be
related to the intervention. In all cases the handling of the SR was
continuously smooth. The median NIHSS 24 h post procedure
was 4.5 (IQR, 1.5–11) and 2 (IQR, 0–5) at discharge.
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TABLE 4 | Overview of recent studies evaluating stent retrievers.
Primary used stent retriever Number of patients First-pass reperfusion rate (%) Final reperfusion rate (%)
mTICI ≥2b ≥2c ≥2b ≥2c
Trevo 2000 Registry
(7, 13)
Trevo XP 2,008 - 27.8% 92.8% 56.4%a
Yi et al. (14) Trevo XP 98 40.8% 89.7%
Solitaire 102 32% 82.3%
ARISE II (15) EmboTrap I and II 227 51.5% 40% 92.5% 76%
Ribo et al. (16) Neva thrombectomy device 30 63% 47% 93% 63%
Velioglu et al. (17) CatchView thrombectomy device 53 47.2% - 84.9% -
Gupta et al. (18) Tigertriever 160 57.8% - 95.7% 71.8%
Kurre et al. (19) pREset stent retriever 271 - - 84.9% -
ARTESp (20) pREset stent retriever 100 - - 85.3% -
Kaschner et al. (21) Aperio thrombectomy device 97 43.9% 15.1% 85.3% 54.8%
Kaschner et al. (22) Aperio Hybrid stent retriever 48 52.1% 31.3% 95.8% 60.4%
Pfaff et al. (23) Solitaire Platinum stent retriever 75 38.6% 92%
Our study Trevo NXT ProVue retriever 80 63.75% 53.75% 96.25% 82.5%
aRefers to mTICI 3 results.
mTICI, modified thrombolysis in cerebral infarction.
A total of 158 passes were performed with the Trevo NXT;
no device malfunctions were observed. Four complications were
reported: 2 SAHs and 2 vasospasms (which resolved after
application of nimodipine). Both vasospasms were observed in
the segment where the SR was placed [one in the M2-segment
of the right middle cerebral artery (MCA) and one in the
M2-segment of the left MCA]. In both cases the Trevo NXT
4× 35 mm SR was used.
A subgroup analysis of the angiographic results after
stratification by occlusion site indicated higher first-pass
complete or near-complete reperfusion results in the M1- and
M2-segments compared to the ICA-T (53%/46% vs. 29%).
Furthermore, the number of passes (median 3 for the ICA-
T and 1 for the M1/M2) and the groin to reperfusion time
(median 51 min for ICA-T vs. 34/35 min for M1/M2) were
higher for ICA-T occlusions (seeTable 2 for detailed results). The
incremental improvement of themTICI result declined from pass
to pass (Table 3).
Advancing the SR was rated “very easy” in 39%, “easy” in 47%,
and “neutral” in 14% of our cases, while none of the procedures
was rated as “hard.” Target placement of the SR was achieved in
all cases. Withdrawing the SR toward the aspiration-catheter to
reach the wedge position or retrieve it toward the BGC was rated
as “very easy” in 51%, “easy” in 42%, and “neutral” in 7%. The
wedge position could be sustained in 91% of the procedures.
DISCUSSION
Early and complete arterial recanalization is the most important
factor in achieving favorable clinical outcome after ischemic
stroke due to LVO (10, 11). Mechanical thrombectomy is the
standard of care for LVO and gaining momentum for medium
vessel occlusions as well, as multiple randomized trials have
demonstrated improved patient outcomes in the interventional
arm (1, 12). In cases of tortuous proximal vessels or distal target
lesions, pushing the SR through the microcatheter and retrieving
the SR within the aspiration-catheter can be challenging. The
design of the new Trevo NXT is supposed to help in these
situations, due to the hydrophilic coating of the pusher wire.
In this retrospective multicenter study, we evaluated the initial
results with this new device. One of our main findings was
that the rate of first-pass complete or near-complete reperfusion
(mTICI ≥2c) was achieved in 54% of cases, which compares
favorably to previously published data of the predecessor
retriever (Table 4) (13, 14). Final mTICI ≥2c was achieved in
83%, and final complete reperfusion (mTICI 3) in 56% of the
cases. First-pass mTICI ≥2c was achieved more often than in
the Trevo 2000 Registry, where the rate was 28% (13). Regarding
final reperfusion rates, mTICI 3 was documented in 56% of the
Trevo 2000 Registry cases, which is identical to the final mTICI 3
rates of our study (56%) (7). Data of other newer-generation SRs
were mostly comparable to our results: Ribo et al. reported 63%
mTICI ≥2b and 47% mTICI ≥2c first-pass reperfusion using the
Neva thrombectomy device, although with a small sample size
of only 30 patients (16). Slightly inferior results with 52% first-
pass mTICI ≥2b and 40% first-pass mTICI ≥2c were reported
in the prospective ARISE II study, where the EmboTrap SR was
assessed using a larger sample size (n = 227) (15). Results of
the Aperio Hybrid SR were recently published, with 52% mTICI
≥2b and 31% mTICI ≥2c first-pass reperfusion in a sample
of 48 patients, which are slightly inferior to our reperfusion
rates (22). The Tigertriever, which can be radially adjusted, was
recently evaluated in the multicentric Tiger Trial (n = 160),
yielding similar reperfusion results with first-pass successful
reperfusion rates of 58% and final near-complete reperfusion
rates of 72% (18). Technical approaches varied within all these
studies, limiting the degree to which reperfusion results can be
compared. For example, while in this study the primarily used
Frontiers in Neurology | www.frontiersin.org 4 July 2021 | Volume 12 | Article 704329
Etter et al. Initial Experience With Trevo NXT
technique was a combined technique (93% of the cases), this
approach was used only in a minority of cases in the Trevo 2000
Registry (7).
Regarding the technical aspects using the Trevo NXT as
first-line device, advancing the SR within the microcatheter
was described as “easy” in the majority of cases, and target
placement of the SR was achieved in all cases. Even in cases
of curved proximal vessels or tortuous siphon we were able to
push the 4 mm Trevo NXT through a 0.021-inch microcatheter
without failing to reach the target position. While treating
distal occlusions with the 3mm Trevo NXT, pushing the
device through a 0.017-inch microcatheter was feasible. In our
subjective opinion, pushing the new 3mm device through a
0.017-inch microcatheter was easier compared to previous Trevo
generations, although we did not compare the 2 devices in
this study. In terms of retrieving the SR into the aspiration-
catheter or the BGC, we also received positive feedback from
the interventionalists. These findings are consistent with the
development of a hydrophilic coated polymer jacket, which
was designed to enable a smoother and easier delivery and an
improved retraction into the aspiration-catheter. Our experience
is that even in tortuous proximal vessels it is much easier to
push a rather rigid large-bore aspiration-catheter toward the face
of the clot over the new SR after removal of the microcatheter.
For physicians using the Solumbra technique (full retrieval of
the SR within the aspiration-catheter) as their primary approach,
the hydrophilic jacket provides an even smoother retrieval
experience compared to older SRs. Nevertheless, we would not
recommend this technique to be used as first-line approach,
based on the higher occurrence of clot fragmentation and distal
emboli (24). A potential disadvantage of the new coating is
encountered when pulling the SR toward the tip of the aspiration-
catheter for the SAVE maneuver (25): With conventional SRs,
there is a point where a wedge position is reached and cannot
be lost even with significant pulling power on the SR wire, due
to entrapment of the clot between the SR and the aspiration-
catheter. Using the new device, we noticed that continuous pull
after reaching the wedge position can lead to unintentional
withdrawal of the SR within the aspiration-catheter (9% of our
cases) resulting in an unintended Solumbra maneuver.
Concerning safety, the Trevo NXT retriever can be regarded
as safe. Complication rates were comparable to those of the
literature (1). Both cases of SAH were unnoticed during the
procedure and could not be clearly attributed to the SR (26).
The main limitation of our study is the retrospective design.
Patients were included after initial stroke incident and treatment
with mechanical thrombectomy. In addition, angiographic
results and complications were rated by the treating physician
and not by a core lab, which can lead to heterogenous judgments
and potentially influence results. Finally, the Trevo NXT was
chosen as the first-line device by the treating physician and not
allotted in a randomized setup.
CONCLUSION
Based on our initial data, we conclude that the Trevo NXT is an
effective and safe tool for mechanical thrombectomy especially
when using combined approaches.
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